Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Hatem A Abdel-Aziz, Wagdy M Eldehna, Adam B Keeton, Gary A Piazza, Adnan A Kadi, Mohamed W Attwa, Ali S Abdelhameed & Mohamed I Attia. (2017) Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling. Drug Design, Development and Therapy 11, pages 2333-2346.
Read now
Read now
AC Backes, B Zech, B Felber, B Klebl & G Müller. (2008) Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opinion on Drug Discovery 3:12, pages 1427-1449.
Read now
Read now
Articles from other publishers (19)
Sara M. Emam, Samir M. El Rayes, Ibrahim A. I. Ali, Hamdy A. Soliman & Mohamed S. Nafie. (2023) Synthesis of phthalazine-based derivatives as selective anti-breast cancer agents through EGFR-mediated apoptosis: in vitro and in silico studies. BMC Chemistry 17:1.
Crossref
Crossref
Khaled El‐Adl, Helmy M. Sakr, Reda G. Yousef, Ahmed B. M. Mehany, Hamada S. Abulkhair & Ibrahim. H. Eissa. (2022)
New quinoxalin‐2(1
H
)‐one‐derived VEGFR‐2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies
. Archiv der Pharmazie 355:7.
Crossref
Crossref
Khaled El‐Adl, Mohamed K. Ibrahim, Fathalla Khedr, Hamada S. Abulkhair & Ibrahim H. Eissa. (2021) Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR‐2 inhibitors. Archiv der Pharmazie 355:1, pages 2100278.
Crossref
Crossref
Khaled El‐Adl, Mohamed‐Kamal Ibrahim, Fathalla Khedr, Hamada S. Abulkhair & Ibrahim H. Eissa. (2020)
N
‐Substituted‐4‐phenylphthalazin‐1‐amine‐derived VEGFR‐2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies
. Archiv der Pharmazie 354:3, pages 2000219.
Crossref
Crossref
Sumera Zaib & Imtiaz Khan. (2020) Synthetic and medicinal chemistry of phthalazines: Recent developments, opportunities and challenges. Bioorganic Chemistry 105, pages 104425.
Crossref
Crossref
Jyoti Singh, Amruta Suryan, Sandeep Kumar & Shweta Sharma. (2020) Phthalazinone Scaffold: Emerging Tool in the Development of Target Based Novel Anticancer Agents. Anti-Cancer Agents in Medicinal Chemistry 20:18, pages 2228-2245.
Crossref
Crossref
Jaiprakash Sangshetti, Shahebaaz K. Pathan, Rajesh Patil, Siddique Akber Ansari, Santosh Chhajed, Rohidas Arote & Devanand B. Shinde. (2019) Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review. Bioorganic & Medicinal Chemistry 27:18, pages 3979-3997.
Crossref
Crossref
Abhishek Ashok, Kannan Thanukrishnan, Halehatty S. Bhojya Naik & Soma Ghosh. (2016) 6,7‐Dimethoxy‐Quinazolin‐4‐yl‐Amino‐Nicotinamide Derivatives as Potent Inhibitors of VEGF Receptor II. Journal of Heterocyclic Chemistry 54:3, pages 1723-1728.
Crossref
Crossref
Wagdy M. Eldehna, Sahar M. Abou-Seri, Ahmed M. El Kerdawy, Rezk R. Ayyad, Abdallah M. Hamdy, Hazem A. Ghabbour, Mamdouh M. Ali & Dalal A. Abou El Ella. (2016) Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives. European Journal of Medicinal Chemistry 113, pages 50-62.
Crossref
Crossref
Sahar M. Abou-Seri, Wagdy M. Eldehna, Mamdouh M. Ali & Dalal A. Abou El Ella. (2016) 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation. European Journal of Medicinal Chemistry 107, pages 165-179.
Crossref
Crossref
Wagdy M. Eldehna, Hany S. Ibrahim, Hatem A. Abdel-Aziz, Noha N. Farrag & Mohieldin M. Youssef. (2015) Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones. European Journal of Medicinal Chemistry 89, pages 549-560.
Crossref
Crossref
Takahiro Honda, Hironori Nagahara, Hiroyuki Mogi, Masakazu Ban & Hiroyuki Aono. (2011) KDR inhibitor with the intramolecular non-bonded interaction: Conformation–activity relationships of novel indole-3-carboxamide derivatives. Bioorganic & Medicinal Chemistry Letters 21:6, pages 1782-1785.
Crossref
Crossref
Frédéric Gaudette, Stéphane Raeppel, Hannah Nguyen, Normand Beaulieu, Carole Beaulieu, Isabelle Dupont, A. Robert Macleod, Jeffrey M. Besterman & Arkadii Vaisburg. (2010) Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups. Bioorganic & Medicinal Chemistry Letters 20:3, pages 848-852.
Crossref
Crossref
Oscar Saavedra, Stephen Claridge, Lijie Zhan, Franck Raeppel, Marie-Claude Granger, Stéphane Raeppel, Michael Mannion, Frédéric Gaudette, Nancy Zhou, Ljubomir Isakovic, Naomy Bernstein, Robert Déziel, Hannah Nguyen, Normand Beaulieu, Carole Beaulieu, Isabelle Dupont, James Wang, A. Robert Macleod, Jeffrey M. Besterman & Arkadii Vaisburg. (2009) N3-Arylmalonamides: A new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorganic & Medicinal Chemistry Letters 19:24, pages 6836-6839.
Crossref
Crossref
Michael Mannion, Stéphane Raeppel, Stephen Claridge, Nancy Zhou, Oscar Saavedra, Ljubomir Isakovic, Lijie Zhan, Frédéric Gaudette, Franck Raeppel, Robert Déziel, Normand Beaulieu, Hannah Nguyen, Ian Chute, Carole Beaulieu, Isabelle Dupont, Marie-France Robert, Sylvain Lefebvre, Marja Dubay, Jubrail Rahil, James Wang, Hélène Ste-Croix, A. Robert Macleod, Jeffrey M. Besterman & Arkadii Vaisburg. (2009) N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 19:23, pages 6552-6556.
Crossref
Crossref
Stéphane Raeppel, Stephen Claridge, Oscar Saavedra, Frédéric Gaudette, Lijie Zhan, Michael Mannion, Nancy Zhou, Franck Raeppel, Marie-Claude Granger, Ljubomir Isakovic, Robert Déziel, Hannah Nguyen, Normand Beaulieu, Carole Beaulieu, Isabelle Dupont, Marie-France Robert, Sylvain Lefebvre, Marja Dubay, Jubrail Rahil, James Wang, Hélène Ste-Croix, A. Robert Macleod, Jeffrey Besterman & Arkadii Vaisburg. (2009) N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 19:5, pages 1323-1328.
Crossref
Crossref
Takahiro Honda, Hisashi Tajima, Yasushi Kaneko, Masakazu Ban, Takaaki Inaba, Yuriko Takeno, Kazuyoshi Okamoto & Hiroyuki Aono. (2008) Conformation–activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity. Bioorganic & Medicinal Chemistry Letters 18:9, pages 2939-2943.
Crossref
Crossref
Philip Wickens, Harold Kluender, Julie Dixon, Catherine Brennan, Furahi Achebe, Antonella Bacchiocchi, Don Bankston, Donald Bierer, Michael Brands, Debbie Braun, Melissa S. Brown, Chih-Yuan Chuang, Jacques Dumas, Istvan Enyedy, Gloria Hofilena, Zhenqiu Hong, Tim Housley, Benjamin Jones, Uday Khire, Charles Kreiman, Ellalahewage Kumarasinghe, Timothy Lowinger, Ronda Ott-Morgan, Louise Perkins, Barton Phillips, Robert Schoenleber, William J. Scott, Ryan Sheeler, Anikó Redman, Xiuying Sun, Ian Taylor, Lei Wang, Scott Wilhelm, Xiaomei Zhang, Mingbao Zhang, Elizabeth Sullivan, Christopher Carter, Mark Miglarese & Joan Levy. (2007) SAR of a novel ‘Anthranilamide Like’ series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer. Bioorganic & Medicinal Chemistry Letters 17:15, pages 4378-4381.
Crossref
Crossref
Matthew A.J. Duncton, Evgueni L. Piatnitski, Reeti Katoch-Rouse, Leon M. SmithIIII, Alexander S. Kiselyov, Daniel L. Milligan, Chris Balagtas, Wai C. Wong, Joel Kawakami & Jacqueline F. Doody. (2006) Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorganic & Medicinal Chemistry Letters 16:6, pages 1579-1581.
Crossref
Crossref